VF
CCCC icon

Virtu Financial’s C4 Therapeutics CCCC Stock Holding History

Virtu Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,655
Closed -$39K – 1697
2025
Q4 		$39K Buy
+20,655
New +$48.9K ﹤0.01% 1332
2025
Q3 		– Sell
-24,377
Closed -$35K – 1518
2025
Q2 		$35K Buy
+24,377
New +$35.5K ﹤0.01% 1184

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial's CCCC Position: Q1 2026 in Review

Virtu Financial sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 20,655 shares — an estimated $39K sold.

Virtu Financial first reported a position in CCCC in Q2 2025 and held it in 2 quarters. The position peaked at $39K in Q4 2025. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Virtu Financial reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Virtu Financial sold 20,655 C4 Therapeutics shares in Q1 2026, an estimated $39K.
  • Virtu Financial first reported a position in C4 Therapeutics in Q2 2025 and held it in 2 quarters.
  • Virtu Financial's C4 Therapeutics position peaked at $39K in Q4 2025.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.